SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vascular Biogenics
VBLT 1.3000.0%Aug 7 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFileNext 10PreviousNext  
From: biorabbi6/4/2016 1:47:31 AM
   of 2
 
Two posters at ASCO coming up. Tomorrow will be VB-111 for rGBM from the phase II trial as compared to historical controls with Avastin. Monday's poster could be more interesting. It will summarize the phase IIa ovarian cancer data with VB-111 looking at progression free survival, change in CA-125 level, possibly overall survival data if mature, and the histology from biopsy results.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFileNext 10PreviousNext